Parkinson Hastalığının Deneysel Nörotoksin Modelleri

Öz

Parkinson hastalığı (PH), bazal gangliyonlardaki dopaminin azalması sonucu gelişen nörodejeneratif bir hastalıktır. Hastalığın patogenezi tam olarak anlaşılamamıştır. Ancak PH‟nın temelinde nöroinflamasyonun olduğu bilinen bir gerçektir. Deneysel modellerde kullanılan bütün nörotoksinler, nigrostriatal yolakta nöroinflamasyon cevabını oluşturmaktadır. Ayrıca, bradikinezi, rijidite ve gönüllü harekete başlama/sıralama bozukluğu da meydana gelmektedir. Dolayısıyla, PH için olası terapötikleri değerlendirmek, hastalıkla ilişkili patolojileri anlamak için hayvan modelleri gereklidir. Motor bozuklukları ölçmede basit ve kolay olması da hayvan modelleriyle çalışmayı daha cazip hale getirmiştir. Bu derlemede, PH araştırmalarında kullanılan nörotoksin hayvan modelleri incelenmiştir.

Anahtar Kelimeler

• Parkinson hastalığı
• Nörotoksinler
• Hayvan modelleri

Kaynakça

1. 1. Ribeiro FM, Camargos ER, de Souza LC, Teixeira AL: Animal models of neurodegenerative diseases. Revista brasileira de psiquiatria 2013, 35 Suppl 2:S82- 91.
2. 2. Baptista MA, Dave KD, Sheth NP, De Silva SN, Carlson KM, Aziz YN, Fiske BK, Sherer TB, Frasier MA: A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research. Disease models & mechanisms 2013, 6:1316-1324.
3. 3. Kaakkola S, Teravainen H: Animal models of parkinsonism. Pharmacology & toxicology 1990, 67:95-100.
4. 4. Duty S, Jenner P: Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. British journal of pharmacology 2011, 164:1357-1391.
5. 5. Grigor'ian GA, Bazian AS: [The experimental models of Parkinson's disease in animals]. Uspekhi fiziologicheskikh nauk 2007, 38:80-88.
6. 6. Jackson-Lewis V, Blesa J, Przedborski S: Animal models of Parkinson's disease. Parkinsonism & related disorders 2012, 18 Suppl 1:S183-185.
7. 7. Chesselet MF, Richter F: Modelling of Parkinson's disease in mice. The Lancet Neurology 2011, 10:1108-1118.
8. 8. Jackson-Lewis V, Blesa J, Przedborski S: Animal models of Parkinson's disease. Parkinsonism & related disorders 2012, 18 Suppl 1:S183-185.

9. 9. Glajch KE, Fleming SM, Surmeier DJ, Osten P: Sensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease. Behavioural brain research 2012, 230:309-316.
10. 10. Schmidt WJ, Alam M: Controversies on new animal models of Parkinson's disease pro and con: the rotenone model of Parkinson's disease (PD). Journal of neural transmission Supplementum 2006:273-276.
11. 11. Schober A: Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell and tissue research 2004, 318:215-224.
12. 12. Blesa J, Phani S, Jackson-Lewis V, Przedborski S: Classic and new animal models of Parkinson's disease. Journal of biomedicine & biotechnology 2012, 2012:845618.
13. 13. Tieu K: A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harbor perspectives in medicine 2011, 1:a009316.
14. 14. Smeyne RJ, Jackson-Lewis V: The MPTP model of Parkinson's disease. Brain research Molecular brain research 2005, 134:57-66.
15. 15.Taylor JM, Main BS, Crack PJ: Neuroinflammation and oxidative stress: coconspirators in the pathology of Parkinson's disease. Neurochemistry international 2013, 62:803-819.
16. 16. Yokoyama H, Kuroiwa H, Kasahara J, Araki T: Neuropharmacological approach against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)-induced mouse model of Parkinson's disease. Acta neurobiologiae experimentalis 2011, 71:269- 280.
17. 17. Bazzu G, Calia G, Puggioni G, Spissu Y, Rocchitta G, Debetto P, Grigoletto J, Zusso M, Migheli R, Serra PA, et al: alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach. CNS & neurological disorders drug targets 2010, 9:482- 490.
18. 18. Blandini F, Armentero MT: Animal models of Parkinson's disease. The FEBS journal 2012, 279:1156-1166.
19. 19. Bove J, Prou D, Perier C, Przedborski S: Toxin-induced models of Parkinson's disease. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics 2005, 2:484-494.
20. 20. Bove J, Perier C: Neurotoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
21. 21. Hare DJ, Adlard PA, Doble PA, Finkelstein DI: Metallobiology of 1-methyl-4- phenyl1,2,3,6-tetrahydropyridine neurotoxicity. Metallomics : integrated biometal science 2013, 5:91-109.
22. 22. Blandini F, Armentero MT, Martignoni E: The 6-hydroxydopamine model: news from the past. Parkinsonism & related disorders 2008, 14 Suppl 2:S124-129.
23. 23. Hirsch EC, Hunot S: Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009, 8:382-397.
24. 24. Li J, Fan Y, Zhang YN, Sun DJ, Fu SB, Ma L, Jiang LH, Cui C, Ding HF, Yang J: The Raf-1 inhibitor GW5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine. Die Pharmazie 2012, 67:718- 724.
25. 25. Simola N, Morelli M, Carta AR: The 6-hydroxydopamine model of Parkinson's disease. Neurotoxicity research 2007, 11:151-167.
26. 26.Ramsey CP, Tansey MG: A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets. Experimental neurology 2014, 256:126-132.
27. 27. Hunter, R. L., Cheng, B., Choi, D. Y., Liu, M., Liu, S., Cass, W. A., & Bing, G. (2009). Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6mice. Journal of Neuroscience Research, 87(8), 1913-1921.
28. 28. Johnson ME, Bobrovskaya L: An update on the rotenone models of Parkinson's disease: Their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2014.
29. 29.Huang CL, Lee YC, Yang YC, Kuo TY, Huang NK: Minocycline prevents paraquatinduced cell death through attenuating endoplasmic reticulum stress and mitochondrial dysfunction. Toxicology letters 2012, 209:203-210.